BeiGene’s Tislelizumab Approved for Gastric Tumors in China
BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has revealed that its programmed death-1 (PD-1) inhibitor...
SciClone Partners with Cowell Health to Enhance Cancer Treatment Accessibility
SciClone Pharmaceuticals Inc. (Nasdaq: SCLN), which became a China-based company after going private in 2017,...
Baheal Pharmaceutical Partners with Novartis for Votrient Commercialization
China-based health services and distribution giant Baheal Pharmaceutical Group has struck a partnership with Swiss...
Grand Pharma’s First-in-Class RDC ITM-11 Accepted for IND Review
China-based Grand Pharmaceutical Group Ltd (HKG: 0512) has announced that an Investigational New Drug (IND)...
Jacobio Pharma Partners with WestChina-Frontier for Preclinical Safety Studies
China-based Jacobio Pharma (HKG: 1167) has announced a partnership agreement with compatriot firm WestChina-Frontier PharmaTech,...
Mabwell’s IL-11 Monoclonal Antibody 9MW3811 Approved for Australian Clinical Trial
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced receiving clinical trial approval from...
AstraZeneca’s Calquence Administered in Hainan Ahead of Official Approval
UK major AstraZeneca’s (AZ, NASDAQ: AZN) blood cancer therapy Calquence (acalabrutinib) was first administered at...
CARsgen Therapeutics Partners with Jinshan Hospital for CAR-T Research
China-based chimeric antigen receptor (CAR)-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced...
Sansure Biotech Partners with Shanghai Tenth People’s Hospital for Genomics Center
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has struck a partnership with Shanghai...
Zhongchao and Johnson & Johnson Renew Partnership for Digital Health Services
Introduction Zhongchao Inc. (NASDAQ: ZCMD), a Shanghai-based online health education provider, has announced a renewed...
CStone’s Sugemalimab Accepted for EU Marketing Authorization by EMA
China-based CStone Pharmaceuticals (HKG: 2616) has announced that the European Medicine Agency (EMA) has accepted...
Danatlas Raises Pre-Series A Funding for Synthetic Lethality Drug Development
Beijing-headquartered Danatlas, a first-in-class drug developer specializing in the synthetic lethality field, has reportedly raised...
CDE Signals Priority Review for Sanofi’s Dupixent and Other Drugs
The Center for Drug Evaluation (CDE) website indicates that France major Sanofi’s (NASDAQ: SNY) Dupixent...
InnoCare and Keymed Announce First Dosing of ICP-B05 Clinical Study
China-based firms InnoCare Pharma (HKG: 9969, SHA: 688428) and Keymed Biosciences (HKG: 2162) have jointly...
Luye Pharma’s Paliperidone Palmitate Approved for European Clinical Trials
China-based Luye Pharma Group (HKG: 2186) has announced receiving clinical trial approval in Europe for...
Bio-Thera Solutions Partners with China Resource Medicine for Integrated Collaboration
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced a strategic partnership with compatriot firm China...
NMPA Approves STmed’s ECMO Product for Market
The National Medical Products Administration (NMPA) has approved STmed Technology’s extracorporeal cardiopulmonary support auxiliary equipment...
Johnson & Johnson MedTech’s QDOT Catheter Approved in China for Atrial Fibrillation
Johnson & Johnson MedTech’s next-generation QDOT micro diagnostic/ablation deflectable tip catheter, a disposable pressure monitoring...
Roche Returns Global Rights to Blueprint’s RET Inhibitor Gavreto
US-based biotech Blueprint Medicines has announced that Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) has...
ConjuStar Peptide-Drug Conjugate Angel Financing
Tianjin-based ConjuStar, a peptide-drug conjugate (PDC) developer incubated by Fosun Pharma and Wuxi Apptec, has...